Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I know nothing about the rights or warrants unfortunately. Maybe it's a crap shoot just in case...........
I just decided to take a shot on the common, although after reading your post, not so sure that it was a good idea....
Best of luck to you and thank you.
Splintered:
I see little near term hope for common shares short of huge positive news on CLR130 clinical trials, Phase 2.
Those trials, and their results, should not take so long in that the one or two one hour infusions at a couple of dosing levels can be quickly analyzed, considering the very short half life of radioactive iodine and the immediate effect of it on various cancer cells.
No, the company knows what the results are by now, and I cannot think of any reason the keep the results secret, unless there are plans to sell the company to big Pharma suitor.
The recent decision to dilute with many more shares and raise capital does not support any M&A possibilities. OCICBW
BUT, I really wonder why the old CLRBZ warrants are holding at the high twenty cent level instead of at five cents like much of last year. CLRBZ warrants expire worthless on 4/8/21, right?. What’s up with that at this point?
Why would someone be acquiring hundreds of thousands of these warrants now???
Just bought some of the common - any hope?
Just bought some of the common - any hope?
Good luck Jakkelp!
I hope you recover losses from December to date on this stock/company.
I got out of my CLRBZ warrants by a fat thumb trade a few weeks ago where someone place a buy order 500% above the market price.
That leaves a thousand CLRB shares to dump. This company and it alleged products/technology has been a big disappointment for years.
I now think if the CLR was going to work well, it would have proven itself by NOW.
The special shareholder meeting at the end of this month with DILUTION becoming official will be the mail in the coffin.
Sunofwolf was right, this company is run for the employees pay, not shareholders and potential patients, OCICBW! Just an opinion based on superficial observations!
Ronjon41:
This biotech stock has been a sleeper for a few years now, holding my money in a lock box. “Dead money”, as Cramer would call it. Since it’s potential products are still all in clinical trial stages, it’s price performance is understandable. Management has not monetized the intellectual property nor helped many patients.
BUT THIS IS CHANGING, NOW!
How do I know this?
Research CLRB’s warrants, trading under the symbol CLRBZ!
I had 10’s of thousands of these warrants in two accounts, with a basis of a few cents. These warrants expire worthless on or about 4/8/21. MY GTC SELL ORDERS ALL TRIGGERED TODAY AT .71 cents- HUGE PROFITS FOR ME IN MY REGULAR IRA AND ROTH IRA. (OF COURSE, I WISH MY SELL ORDERS WERE TWICE AS HIGH, since CLRBZ spiked to $1.50 or so TODAY.)
I believe these most of these warrants are owned by INSIDERS with more information than I have about CLRB & its clinical trial results !!!
I humbly believe that the price action of CLRBZ is a very good indication off the future for the stock CLRB itself- although I could be wrong again!
Everyone, do your own research & Ignore me- and my speculative opinions!
Why isn't anyone talking about this stock? Why did it run so hard?
Worth repeating 1/7/21 PR:
“Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced median overall survival (mOS) in Cohorts 1-4 of the company’s ongoing Phase 1 clinical trial evaluating CLR 131 for the treatment of relapsed/refractory (R/R) multiple myeloma (MM). The results showed mOS of 22.0 months among 15 patients, all of whom were heavily pretreated, averaging five prior lines of systemic therapy. Each patient in Cohorts 1-4 of this dose-escalation study received a single 30-minute infusion of CLR 131.
All patients enrolled in Cohorts 1 through 4 were previously treated with both proteasome inhibitors and immunomodulatory drugs, and experienced disease progression with greater than one-third dual refractory. While no head-to-head studies have been conducted between CLR 131 and other therapies in this heavily pretreated population, for background purposes, a 2016 article published in the journal Bone Marrow Transplantation refractory to both proteasome inhibitors and immunomodulatory drugs achieve mOS of 9 months.1 Additionally, mOS for R/R MM patients receiving treatment in third line averages approximately 12 months of survival, including several recently approved drugs.2,3...”
Editorial Comment:
WHAT WOULD YOU PAY FOR AN EXTRA 22 months of life, if you had the money???
“...The median overall survival of 22 months in this heavily pretreated patient population is very encouraging. These are patients with limited therapeutic options and, unfortunately, face poor prognoses,” said James Caruso, president and chief executive officer of Cellectar Biosciences. “The convenience afforded by CLR 131 delivered in only one or two doses as currently administered in our ongoing hematology studies makes it a far less intrusive regimen than other treatments that must be administered at regular dosing intervals. We believe extending mOS with a more patient-friendly dosing regimen provides both a distinctive product profile and the potential to provide beneficial patient outcomes even in later lines of therapy.”
1. R.F Cornell and A.A. Kassim (2016). Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Journal of Bone Marrow Transplantation
2. Jurczyszyn et al (2014). New drugs in multiple myeloma – role of carfilzomib and pomalidomide. Contemporary Oncology
3. Dimopolous et al (2016). Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple...”
1/27/21: EU grants CLRB orphan drug status on specific blood cancer!
But this is not the U S clinical news on 131 that is promised soon.
Time will tell!
Seeking Alpha article on CLRB:
https://seekingalpha.com/news/3654903-cellectars-clr-131-an-orphan-drug-in-european-for-rare-blood-cancer
FASTEN YOUR SEAT BELTS, Robinhood traders are coming here soon!
Due for clinical trial news?
IR thinks so...good or fluff bad?
Big “D” always hurts
for awhile...if the company is truly growth and earnings orientated.
THEIR (CLRB) FUND RAISING (DILUTION) HAS TO BE USED TO COMPLETE DEVELOPMENT OF A CANCER TREATMENT OR THE PAID BEARS HERE WILL BE RIGHT. IT’s either win/WIN OR lose/LOSE IN THIS MARKET OR ESPECIALLY THE 2021 ONE TO COME!
And now 25% down since 22nd December close... It was a brutal fundraiser- very dilutive...
Hope to recoup my losses beginning of January - trial update(s) are due.
CLRB UP 2days in a row,
..:With no news that I can find.
$3 inter-day yesterday?
There is no explanation but volume will tell if it is only manipulation of share price.
IT IS CHEAPER AND BETTER LEVERAGE TO USE CLRBZ TO SPECULATE ON THIS COMPANY FOR THE NEXT 30 days ONLY!
JACK, be nimble; JACK BE QUICK!
I stop buying stocks after seeing how much fraud is involved. This company thinks 4 people is a study. the tech doesn't work and is a fake.
If so, where is the “pump”?
Where are the unsubstantiated company press releases, reflecting the pump?
I just this week flipped thousands of .08 cent warrants (CLRBZ) for over .27 cents...3 baggers are profitable!
You make a few good points, but trading volatility is just dating, not marriage!
CLRB, a pump and dump, as usual. What the company has are like garbages.
The warrants CLRBZ are worth of $0 as the strick prices are at $30.4 while CLRB is just $1.9.
CLRBZ:
April 2016 Underwritten Registered Warrants: strike price: $30.40,
Exp. April 20,2021
* * $CLRB Video Chart 12-02-2020 * *
Link to Video - click here to watch the technical chart video
CLRB is UP AGAIN this Wednesday in Pre-market trading,
and on over 100,000 shares traded.
CLRBZ is up again about 20% in pre-market after CLRBZ warrants were up 95% yesterday in day sesion!
WHERE IS THE PAID “boy who cried wolf”? Son of a gun is MIA...
I like the $1.77 high today!
...And on better volume of a few hundred thousand shares!
I assume a 20 odd percent gain for CLRB AT CLOSE AND A 95% gain on CLRBZ warrants was result of inside info leaking on clinical trial data...
sure that's not sonofawolf oil your peddling?
snakeoil company just disappear instantly.
What a big winner this company will be,
My Q1 2021 target is $2.75+ pps, based upon clinical trial news on MM and specific pediatric cancer applications with FDA emergency approvals for both. Good for patients and good for CLRB revenue; win/win!
Ya watching it go down every day, this company is a 100% fraud and why I stopped trading stocks and pulled all my money out.
must be insider trading which is illegal!
Crusader,
Something big is going on behind the scenes.. WHY would the Z warrants
explode up and the common stay put yesterday..
CLRBZ: up over 700%
On heavy volume of over 800,000 warrants traded.
INSIDE INFORMATION??? No public news yet?
THIS PRICE ACTION FOR CLRBZ SEEMS TOO DELAYED TO BE RELATED TO ORR NEWS.
WHAT COULD THE INSIDE INFORMATION BE HERE???
SBOX,
Why do you think the "z" warrantS skyrocketed today?
Would love to hear your thoughts.. They touched $1.54 this morning.
Improves the ORR in all MM populations previous read out vs new read out i 60 mCi.
Tripple refractory 33% --> 40% >=60mci (the PR)
Quad/penta refractory 40% --> 53.8% >= 60mci
High Risk 50% 75 --> 62.5% >= 60 mci
6 or more lines prior 42.8% --> 47.1% >=60mci
NB!! trial continue to be ongoing - so dual dosing data coming up next ??
Sunofwolf, you been right about this stock for long, but reversal is here, get onboard and get a smile on your face
Bouncing off the EM2.
https://stocktwits.com/SeraAnalytica
News release is nothing more than miss info- 40% by who's opinion, some paid quack doctor? clrb does nothing butt steal money from investors for a fat CEO in NJ who spends like crazy on a free fancy office for himself.
Cellectar can beat that ! Belantamab just approved for R/R MM with 4 prior lines of therapy including immunomodulatory drug (IMiD), a proteasome inhibitor, and an anti-CD38 antibody, with ORR/PFS which I believe CLR-131 will match and with a much better AE profile.
Top sales estimate 2026 $1,5B based on current indications/trials, but a lot of new indications could be added down the line for Belantamab.
Looking very much forward to their pediatric neuro oncology data in December.
https://investor.cellectar.com/press-releases/detail/245/cellectar-announces-poster-presentation-at-the
Too easy to manipulate, and too many short term investors.
suk you in then thing falls like a meteor-LOL!
some worthless news, to get people to buy a little while every time goes nowhere. Insiders always dump on news.
Great volume premarket on cancer news
Should see nice pop on open
Can we get a new 52 week high?
Some highlight from the paragraph about CLR-131.
CLR-131 exploit the altered lipid composition of cancer cell membranes to more actively target tumors and deliver the radioactive payload into the cancer cell.
Advantages of this system include the PDCs’ ability to gain entry into a wide variety of cancer types and indiscriminately target all cells within a tumor without relying on expression of a specific antigen.
Furthermore, this technology could offer considerable flexibility in the types of payloads that can be used.
Cellectar has several other PDCs in preclinical development.
CLR 131 could be the first of many such drugs from Cellectar, with other payloads being explored.
That doesn't make Cellectar a fraud just bad management in your view. But the oncology society seems to think CLR-131 is pretty fantastic. This is a great article explaining what CLR-131 (PDCs) is about. But I suspect you already know.
https://www.onclive.com/view/clr-131-leads-a-new-generation-of-lipid-based-cancer-drug-delivery-systems
That doesn't make Cellectar a fraud just bad management in your view. But the oncology society seems to think CLR-131 is pretty fantastic. This is a great article explaining what CLR-131 (PDCs) is about. But I suspect you already know.
https://www.onclive.com/view/clr-131-leads-a-new-generation-of-lipid-based-cancer-drug-delivery-systems
Why I know this company is a fraud. The thing this company ever made that made money came from investors. The CEO covers up spending tons of money for his own fancy office in NJ. It has farmed out all its drug making to a unreliable company in Canada that none else really does business with. Only puts out news when insiders have stock they want to sell that they got for free. None can understand what they are actually doing-which is nothing but stealing money from investors.
Pt Barnum had a famous quote- (a sucker is born every Minute] LOL!
European patent granted !! Loading up shares.
https://data.epo.org/publication-server/pdf-document?pn=3229810&ki=B1&cc=EP
Followers
|
122
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8169
|
Created
|
08/01/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |